The new Abilify Maintena (aripiprazole) will put more focus on avoiding mix-ups with intramuscular "atypical" antipsychotics

May 2014

The new Abilify Maintena (aripiprazole) will put more focus on avoiding mix-ups with intramuscular "atypical" antipsychotics.

Abilify Maintena will be the THIRD long-acting injectable atypical antipsychotic on the market...and will join Invega Sustenna (paliperidone) and Risperdal Consta (risperidone).

These are alternatives to oral antipsychotics for patients with schizophrenia and other psychiatric disorders.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Respiratory & Allergy when and how to use spacers with metered-dose inhalers (MDIs)
Antipsychotics The new Abilify Maintena (aripiprazole) will put more focus on avoiding mix-ups with intramuscular "atypical" antipsychotics
Cardiology new approaches to improve medication use in patients who have had a recent heart attack or "MI" (myocardial infarction)
Vaccines more focus on dispensing typhoid vaccines
Testosterone The debate about treating "low T" in older men will heat up
Elderly Patients avoiding high-risk meds in the elderly
PCOS changes in treatment of polycystic ovary syndrome (PCOS)
Supplements Patients are asking if multivitamins are beneficial
Diabetes meds can increase the risk of diabetes
Anticoagulants handling Rxs for oral blood thinners (warfarin, Pradaxa, Xarelto, etc)

The new Abilify Maintena (aripiprazole) will put more focus on avoiding mix-ups with intramuscular "atypical" antipsychotics

Practical advice for a better career, with unlimited access to CE

Table of Contents